Yahoo Finance7d
SCORE analysis of semaglutide 2.4 mg demonstrated risk reduction in cardiovascular events in a real-world setting
risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients in the U.S. with obesity or overweight and ...
Medscape8d
Semaglutide Shows Major Benefits in Peripheral Arterial Disease: STRIDE
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Clinical Advisor3d
Oral Semaglutide Elicits Superior Cardiometabolic Effects in T2D
Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.
FOX59 News8d
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established ...